672325-36-9 Usage
Uses
Used in Pharmaceutical Industry:
(3R)-1-(2-Aminoethyl)-3-pyrrolidinol is used as a chiral building block for the synthesis of pharmaceuticals, contributing to the development of enantiomerically pure drugs with improved therapeutic effects and reduced side effects.
Used in Agrochemical Industry:
(3R)-1-(2-Aminoethyl)-3-pyrrolidinol is used as a chiral building block in the synthesis of agrochemicals, enabling the production of enantiomerically pure active ingredients with enhanced efficacy and selectivity in crop protection.
Used in Fine Chemicals Industry:
(3R)-1-(2-Aminoethyl)-3-pyrrolidinol is used as a chiral building block in the synthesis of other fine chemicals, such as fragrances, flavors, and specialty chemicals, where enantioselectivity is crucial for desired properties and performance.
Used as a Chiral Resolving Agent:
(3R)-1-(2-Aminoethyl)-3-pyrrolidinol is used as a chiral resolving agent to separate enantiomers of chiral compounds, facilitating the production of enantiomerically pure substances for various applications, including pharmaceuticals, agrochemicals, and other industries.
Used as a Ligand in Asymmetric Catalysis:
(3R)-1-(2-Aminoethyl)-3-pyrrolidinol is used as a ligand in asymmetric catalysis, enhancing the selectivity and efficiency of catalytic reactions, leading to the production of enantiomerically pure products with improved yields and reduced waste.
Check Digit Verification of cas no
The CAS Registry Mumber 672325-36-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,7,2,3,2 and 5 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 672325-36:
(8*6)+(7*7)+(6*2)+(5*3)+(4*2)+(3*5)+(2*3)+(1*6)=159
159 % 10 = 9
So 672325-36-9 is a valid CAS Registry Number.
InChI:InChI=1/C6H14N2O/c7-2-4-8-3-1-6(9)5-8/h6,9H,1-5,7H2/t6-/m1/s1
672325-36-9Relevant academic research and scientific papers
SAR study of bicyclo[4.1.0]heptanes as melanin-concentrating hormone receptor R1 antagonists: Taming hERG
Su, Jing,McKittrick, Brian A.,Tang, Haiqun,Burnett, Duane A.,Clader, John W.,Greenlee, William J.,Hawes, Brian E.,O'Neill, Kim,Spar, Brian,Weig, Blair,Kowalski, Timothy,Sorota, Steve,Li, Cheng,Liu, Tongtong
, p. 5369 - 5385 (2008/03/14)
To improve the ex vivo potency of MCH inhibitor 1a and to address its hERG liability, a structure-activity study was carried out, focusing on three regions of the lead structure. Introduction of new side chains with basic nitrogen improved in vitro and ex
